Pfizer to present new cancer drug data at ASCO 2016

Pfizer has announced that it will be presenting a number of new insights into its cancer drug portfolio at the American Society of Clinical Oncology (ASCO) 2016 annual meeting.

The conference runs from June 3rd to 7th in Chicago and will see the company present more than 40 abstracts, addressing numerous cancers and mechanisms of action.

A total of eight oral presentations and five poster discussions will span Pfizer's internal and collaborative scientific advances, with highlights including the first presentation of a novel immunotherapy combination study involving a 4-1BB agonist and checkpoint inhibitor as a potential new immunotherapy strategy.

Clinical data featuring the new drugs Ibrance and Xalkori will also be discussed, in addition to presentations on avelumab – an anti-PD-L1 IgG1 monoclonal antibody developed in collaboration with Merck – and the next-generation ALK/ROS1 tyrosine kinase inhibitor lorlatinib.

Liz Barrett, global president and general manager at Pfizer Oncology, said: "We look forward to sharing our findings with the entire oncology community with the hope that our collective efforts will continue to advance innovative approaches and redefine life with cancer."